tbuckley/cabot-search huggingface dataset:
Use of Endobronchial Ultrasound and Endoscopic Ultrasound to Stage the Mediastinum in Early-Stage Lung Cancer
Authors: Christopher Gilbert, Lonny Yarmus, David Feller-Kopman
Journal: Journal of the National Comprehensive Cancer Network (2012)

Lung cancer remains the deadliest cancer, with more than 160,000 deaths and 226,000 newly diagnosed cases estimated in 2012. Because treatment and survival are directly linked to disease stage, accurate staging in all patients is crucial. The proper staging of early-stage lung cancer involves investigation for the presence of metastatic spread via lymph nodes within the thorax. Initial steps include CT and PET. Mediastinoscopy has previously been considered the gold standard for mediastinal lymph node sampling; however, over the past 10 years the use of ultrasound-guided lymph node sampling has been shown to be at least as sensitive, and has the added advantage of being able to access significantly more stations. This article reviews the current standards of lung cancer staging in 2012.
Bioactive Anti‐Thrombotic Modification of Decellularized Matrix for Vascular Applications
Authors: Jeremy J. Glynn, Monica T. Hinds
Journal: Advanced Healthcare Materials (2016)

The decellularized matrix derived from porcine small intestinal submucosa (SIS) is a widely used biomaterial being investigated for numerous applications. Currently, thrombus deposition and neointimal hyperplasia have limited the use of SIS in some vascular applications. To limit these detrimental processes, this work applies bioactive, endothelial‐inspired properties to the material. SIS is modified with the endothelial cell membrane protein thrombomodulin and the glycosaminoglycan heparin to facilitate protein C activation and anticoagulant activity, respectively. Modifying SIS with thrombomodulin alone enables robust activated protein C (APC) generation, and thrombomodulin activity is maintained after prolonged exposure to fluid shear and blood plasma. Heparin‐modified SIS has a potent anticoagulant activity. When both modifications are applied sequentially, SIS modified first with thrombomodulin then with heparin retains the full activity of each individual modification. Tubular SIS devices are connected to a baboon arteriovenous shunt to quantify thrombus deposition on these materials. After being exposed to flowing whole blood for 60 min, SIS devices modified first with thrombomodulin then with heparin have significantly less platelet accumulation compared to unmodified SIS devices. These studies demonstrate that modifying SIS with thrombomodulin and heparin confers APC generation and anticoagulant activity that results in reduced thrombogenesis.
Identification of a Leukemia-Associated Antigen of Human Acute Lymphocytic Leukemia23
Authors: Bruce C. Velt, Susan L. Melvin, W. Paul Bowman
Journal: JNCI Journal of the National Cancer Institute (1980)

A human leukemia-associated antigen (LAA) has been identified by immunofluorescence and electrophoretic analyses. LAA was detected on the surfaces of cells from patients with acute lymphocytic leukemia (ALL) as well as on the surfaces of leukemia cells from the established cell lines NALM-1, NALM-16, MOLT-4, CCRF-CEM, and RPMI 8402. The antigen was not detected on BALM-1 or Raji cells (established B-cell lines), bone marrow cells from ALL patients in remission, or on blood lymphocytes from normal donors. This antigen was most frequently associated with common ALL (cALL); however, cells from 2 of 12 patients with T-cell ALL and 1 patient with B-cell ALL also expressed this antigen. Under reduced conditions, the antigen had an approximate molecular mass of 100,000 daltons as determined by sodium dodecyl sulfate--polyacrylamide gel electrophoresis and autoradiographic analysis and appeared to be the same cALL antigen that has recently been described by others. The probability that LAA is a normal differentiation antigen was discussed.
The Future of Chiropractic: A Psychosocial View
Authors: Gregory J. Firman, Michael S. Goldstein
Journal: New England Journal of Medicine (1975)

As the total health-care delivery system in the United States has come under increasing public scrutiny, the role of chiropractic has become of interest. An overview of chiropractic, with an analysis of its social functions and a projection of its future indicates that chiropractic is more congruent with the values of its lower-middle-class clientele than is orthodox medicine. Chiropractors function adquately to legitimize their patients' entrance into the "sick role" and to provide an alternative channel to therapy. The marginal role of the chiropractor in the health-care system, as compared to that of the physician, is stable and functional for the chiropractors thenselves, as well as for their patients. Chiropractic likewise serves the physician, both as a boundary-defining mechanism and as a means of disengagement from troublesome patients. For these reasons, we believe that the role of chiropractic within the health-care system will remain stable in the future.
Studies of Parents of Children With Acute Leukemia 2
Authors: Hie-Won L. Hann, W. Thomas London, Alton I. Sutnick, Baruch S. Blumberg, Edward Lustbader, Hyder M. Carim, Audrey E. Evans, Humphrey E. M. Kay, Ian C. M. MacLennan
Journal: JNCI Journal of the National Cancer Institute (1975)

In a case-control study, 70 mothers and 24 fathers of children with acute leukemia (AL) were compared with 70 mothers and 24 fathers of normal children. Three significant differences (P<O.05) were found when 35 factors were compared among the mother pairs and one difference among the father pairs. Mothers of children with AL, though alike in most respects to their matched controls, had a significantly lower number of monocytes than their controls. This was a new observation. The mothers of the children with AL also had higher levels of γ-globulin, IgA, and IgG (Philadelphia only), which confirmed previous observations. The fathers and mothers had higher levels of basophils. These findings direct attention to the immune systems, particularly the mononuclear cells, of the parents of children with AL, as a focus for further studies on the etiology and pathogenesis of childhood leukemia.
Intermediate Results of Treatment of Primary Mediastinal Large В-Cell Lymphoma with Da-Epoch-R Regimen
Authors: I. Stepanishyna, I. Kryachok, I. Titorenko, K. Filonenko, A. Martynchyk, O. Novosad, V. Sokolov, R. Vereschako
Journal: Annals of Oncology (2014)
Case 31-1994
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Joel M. Gore, John T. Fallon
Journal: New England Journal of Medicine (1994)

Presentation of CaseA 25-year-old man was admitted to the hospital because of the recent onset of congestive heart failure and atrial fibrillation.The patient had been well until four months earlier, when he had a severe upper respiratory tract infection, which resolved with one week of bed rest at home. Two months before admission he was admitted to another hospital because of polydipsia, polyuria, polyphagia, and a weight loss of 9 kg. The blood glucose concentration was as high as 437 mg per deciliter (24.3 mmol per liter). Radiographic study of the chest and an ultrasonographic examination of the . . .
Hemangiopericytoma Involving a Kidney
Authors: Leonard E. Berk, A. Ilhan Erinc, Richard G. McManus
Journal: New England Journal of Medicine (1960)

THE term hemangiopericytoma was first given to a particular type of vascular tumor by Stout and Murray1 in 1942. Now a fairly well defined clinical and pathological entity, it may occur wherever there are capillaries but is most frequent in the superficial soft tissues. In the literature, however, we could find only 1 case (reported by Black and Heinemann2 in 1955) involving the kidney.Case ReportH.N. (W.P.H. 113–991), a 41-year-old woman, was admitted to the hospital on November 22, 1959. She was referred by her family physician because of an asymptomatic left-upper-quadrant mass discovered during a physical examination for . . .
CAF in metastatic breast cancer: standard therapy or another effective regimen?
Authors: D F Hayes, I C Henderson
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.10.1497 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3309195 CAF in metastatic breast cancer: standard therapy or another effective regimen? D F HayesxD F HayesSearch for articles by this author , I C HendersonxI C HendersonSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.10.1497 First Page PDF © 1987 by American Society of Clinical Oncology
Associations between advanced cancer patients’ end-of-life conversations and cost experiences in the final week of life
Authors: B. Zhang, A. A. Wright, M. E. Nilsson, H. A. Huskamp, M. L. Maciejewski, C. C. Earle, P. K. Maciejewski, E. D. Trice, S. D. Block, H. G. Prigerson
Journal: Journal of Clinical Oncology (2008)

9530 Background: Aggressive medical care of cancer patients at the end-of-life (EOL) has been shown to place a large economic burden on society. In a recent study, EOL discussions between advanced cancer patients and physicians were associated with lower rates of aggressive interventions. The aim of this study is to examine the cost differences in EOL care between cancer patients who did or did not report EOL conversations. Methods: Coping with Cancer is an NCI/NIMH-funded, prospective, longitudinal, multi-institutional study of 603 advanced cancer patients. Patients were interviewed at baseline and followed through death. Costs for ICU/hospital stays, daily hospice care and aggressive procedures (e.g., ventilation, resuscitation) received in the last week of life were aggregated. Generalized linear models were applied to test whether patients reporting EOL conversations had lower aggregate costs for care in the week prior to death compared with those who did not. Propensity score matching was used to reduce potential biases associated with patients’ report of an EOL discussion. Results: 188 of 603 patients (31.2%) reported EOL discussions with physicians at baseline. After propensity score matching, the remaining 148 patients (of 323 who died) did not differ in socio-demographic characteristics, psychological measures, treatment preferences, attitudes toward doctors or terminal illness acknowledgement. Further analyses, adjusted by quintiles of predicted propensity scores and key variables of age, sex, race and education, revealed that the aggregate costs of care were $2097 (SE=178) for patients who reported EOL discussions compared with $2970 (SE=271) for patients who did not in 2008 US dollars. The costs of care were 30% lower among those who reported EOL discussions compared to those who did not (cost difference=$874; p-value=0.015). Conclusions: Advanced cancer patients who reported EOL conversations with physicians had significantly lower health care costs in their final week of life. If extrapolated to the national level, based on the number of US cancer deaths/year, these data suggest a difference in EOL care expenditures of $304,539,932 between individuals who had EOL discussions and those who did not. No significant financial relationships to disclose.
Phase II study on the combination carboplatin-celecoxib in heavily pre-treated recurrent ovarian carcinoma patients
Authors: F. Legge, V. Salutari, A. Paglia, A. Testa, D. Lorusso, M. Colangelo, S. Kaye, G. Scambia, G. Ferrandina
Journal: Journal of Clinical Oncology (2006)

15009 Background: Cyclooxygenase-2 (COX-2) has been shown to be involved in several steps of ovarian onset and progression and its overepression is associated with a poor chance of response to chemotherapy and poor prognosis in ovarian cancer. Celecoxib, an orally active selective COX-2 inhibitor, has been tested for its ability to potentiate the activity of carboplatin in treatment of heavily pretreated recurrent ovarian cancer patients. Methods: A phase II study was planned, considering the regimen active if at least 12 responses were observed among the 43 enrolled patients. Celecoxib (400 mg/die), and carboplatin (5 AUC) q28 were administered, until progression or unacceptable toxicity. Response was assessed by RECIST and also by Rustin criteria. Results: 34 pts (median age: 60 yrs, range 28–74) and an ECOG performance status (0/1/2) of (21/12/1), were enrolled. 58.8% of patients were platinum resistant (progressing during or &lt; 6 months from primary treatment). Median number of previous chemotherapy regimens was 3 (range 2–6). Currently 27 patients are evaluable for response. The overall response rate (CR and PR) was 25.9% (2 CR, 5 PR) with stabilization of disease in 8 patients (29.6%). Four responses occurred in platinum sensitive and 3 in platinum resistant group Median time to response was 11 weeks (range 9–19) and median duration of response was 23 weeks (range 12–39). According to Rustin criteria 10 patients out of 25 (40%) were considered responsive to treatment (return of CA125 levels to normal level or &gt;50% reduction). Overall, 143 cycles were administered with a median value of 3 cycles (range = 1–10). Moderate/severe toxicities were as follows: G3 anemia occurred in 2.3% cycles, G3 neutropenia in 4.6% cycles, G3 thrombocytopenia in 1.5% cycles, G3/4 gastrointestinal toxicity occurred in 4.6% cycles. Cutaneous diffuse erithema was observed in 2 patients, in both cases recovered with a short period of antihistaminic treatment; 2 cases of hypertension were documented, G2 hypersensitivity reactions during carboplatin infusion were observed in 4 cases. Conclusions: Celecoxib combined with carboplatin is well tolerated and has promising activity as salvage treatment in heavily pretreated recurrent ovarian cancer patients. No significant financial relationships to disclose.
<i>Vibrio fetus</i>Infection in Man
Authors: Richard L. Kahler, Huntington Sheldon
Journal: New England Journal of Medicine (1960)

VIBRIO fetus is an important cause of infectious abortion in cattle and sheep1 , 2: however, reports of human infection are rare. Since this infection was recently observed in 3 patients at the Johns Hopkins Hospital, it was thought worth while to describe these cases and to review the previous literature concerning V. fetus infection in man.Case ReportsCase 1. A 67-year-old Negro sheet-metalworker (J.H.H. 795641) was seen with thrombophlebitis, fever and cardiac arrhythmia in the Emergency Room of the Johns Hopkins Hospital on January 8, 1958. His health had been good until July, 1957, when he noted the onset . . .
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
Authors: Stefan D. Anker, Stefan Schroeder, Dan Atar, Jeroen J. Bax, Claudio Ceconi, Martin R. Cowie, Adam Crisp, Fabienne Dominjon, Ian Ford, Hossein‐Ardeschir Ghofrani, Savion Gropper, Gerhard Hindricks, Mark A. Hlatky, Richard Holcomb, Narimon Honarpour, J. Wouter Jukema, Albert M. Kim, Michael Kunz, Martin Lefkowitz, Chantal Le Floch, Ulf Landmesser, Theresa A. McDonagh, John J. McMurray, Bela Merkely, Milton Packer, Krishna Prasad, James Revkin, Giuseppe M.C. Rosano, Ransi Somaratne, Wendy Gattis Stough, Adriaan A. Voors, Frank Ruschitzka
Journal: European Journal of Heart Failure (2016)
Abstract 2071: Disruption of TGFβ-mediated tumor suppression in a Tpl2 model of cutaneous squamous cell carcinoma
Authors: Lauren Falkenberg, J. Curtis Gwilliam, Katie L. Decicco-Skinner
Journal: Cancer Research (2015)

Abstract Skin cancer is the most common form of cancer in the United States, with an estimated two million cases diagnosed annually, and incidence continues to increase. Tpl2 (Map3k8) is a serine threonine protein kinase in the mitogen-activated protein kinase (MAPK) signal transduction cascade. Previous studies have shown that Tpl2-/- mice develop significantly more skin tumors than matched wildtype controls and keratinocytes harvested from Tpl2-/- mice display multiple biomarkers for cutaneous squamous cell carcinoma (cSCC.) We have previously established that crosstalk between Tpl2-/- keratinocytes and dermal fibroblasts contributes to the transformative potential of our model, and we hypothesized that one of the possible mechanisms driving this transformation was dysregulation of the TGFβ pathway, which plays multiple roles in carcinogenesis but is known to have an anti-proliferative function in noncancerous cells. Using various techniques, including real-time polymerase chain reaction, matrix-metalloproteinase zymography, in vitro angiogenesis assays, and immunoblotting, we saw that both Tpl2-/- keratinocytes and dermal fibroblasts secreted less TGFβ and displayed significant dysregulation of multiple components of the TGFβ pathway. In summary, our studies demonstrate that loss of Tpl2 results in disruption of TGFβ-mediated tumor suppression, and that disruption is in part caused by abnormal signalling from fibroblasts in the tumor microenvironment. Citation Format: Lauren Falkenberg, J. Curtis Gwilliam, Katie L. Decicco-Skinner. Disruption of TGFβ-mediated tumor suppression in a Tpl2 model of cutaneous squamous cell carcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2071. doi:10.1158/1538-7445.AM2015-2071
Abstract 3129: miR-340 is a modulator of oncogenic signaling in melanoma
Authors: Ashley M. Poenitzsch Strong, Emily G. Adochio, Vijayasaradhi Setaluri, Vladimir S. Spiegelman
Journal: Cancer Research (2015)

Abstract Melanoma is responsible for only 4% of skin cancer diagnoses; nonetheless 80% of skin cancer deaths are attributed to this aggressive skin cancer each year. Growing evidence points to an important role miRNAs may play in the aberrant cellular signaling of cancers, including melanoma. microRNAs (miRNAs) are highly conserved 22-25nt non-coding RNAs involved in regulating RNA stability and translation and are predicted to regulate ∼60% of the human transcriptome. We are investigating the tumor suppressor role miR-340 plays in the development and progression of melanoma. A limited number of miR-340 targets were previously characterized, however, it is unlikely the effects of miR-340 on the melanoma phenotype are the result of directly targeting a few mRNAs, as miRNAs are likely to target upwards of 100 mRNAs each. Using an in silico target identification and pathway mapping system, we identified a multitude of potential miR-340 mRNA targets that encode proteins distributed amongst a variety of cellular signaling pathways. In silico analysis revealed a high proportion of miR-340 predicted mRNA targets that encode for members of the MAPK signaling pathway. Our results show that miR-340 modulated most of the assayed mRNAs that encode MAPK components. We also demonstrate that miR-340 inhibits the tumorigenic phenotype of melanoma cells. We recently developed a novel method to identify direct targets of miRNAs. Using this method, we demonstrate miR-340 directly targets mRNAs that encode protein kinases of the MAPK pathway. Further direct target identification is crucial toward understanding the role miR-340-directed regulation plays in triggering pleiotropic effects during melanoma development and progression. Elucidating the roles aberrant gene regulatory networks play in melanoma is critical for understanding the disease and developing treatment options to improve the melanoma prognosis. Supported by NIH grants ES007015 (to A.M.P.S.), AR063361 (to V.S.S.) and CA191550 (to V.S.S.). Citation Format: Ashley M. Poenitzsch Strong, Emily G. Adochio, Vijayasaradhi Setaluri, Vladimir S. Spiegelman. miR-340 is a modulator of oncogenic signaling in melanoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3129. doi:10.1158/1538-7445.AM2015-3129
Pancreatic Carcinoma with Unusual Metastasis to the Skin and Subcutaneous Tissue Simulating Cellulitis
Authors: Joseph M. Edelstein
Journal: New England Journal of Medicine (1950)

IT IS the object of this report to call attention to an unusual metastasis of pancreatic carcinoma, simulating cellulitis, and to re-emphasize the importance of early, prompt biopsy.Case ReportA 60-year old Navajo was referred to the Navajo Medical Center from the United States Indian Hospital, Shiprock, New Mexico, because of a hard cutaneous and subcutaneous swelling of the right side of the face and neck, and suprasternal area that was progressive and had begun with a small pimple of the right cheek 3 or 4 weeks previously. There had been progressive difficulty in swallowing as well as hoarseness. . . .
P218 The epidemiological, healthcare and societal burden and costs of asthma in the UK and member nations: analyses of national databases
Authors: M Mukherjee, A Stoddart, R Gupta, B Nwaru, M Heaven, A Farr, D Fitzsimmons, A Bandyopadhyay, C Aftab, C Simpson, R Lyons, C Fischbacher, C Dibben, M Shields, C Phillips, D Strachan, G Davies, B McKinstry, A Sheikh
Journal: Thorax (2015)

<h3>Background</h3> Developing a comprehensive picture of the burden of asthma in the UK will enable informed national decisions about care provision and planning. We sought to provide the first UK-wide estimates of the epidemiology, healthcare utilisation and costs of asthma. <h3>Methods</h3> We undertook analyses of national health surveys, routine healthcare and administrative datasets over the period 2010–12. Economic modelling was carried out to estimate costs. Estimates were calculated for each nation and the UK as a whole. <h3>Results</h3> The UK lifetime prevalence of patient-reported symptoms suggestive of asthma in 2010–11 was 30.7% (95% Confidence Intervals [CI] 29.2–32.2; equivalent to [~] 18,949,516 people), lifetime prevalence of patient-reported physician-diagnosed asthma was 15.9% (95% CI 14.7–17.1; ~10,841,030 people), annual prevalence of patient-reported physician-diagnosed-and-treated asthma was 9.1% (95% CI 8.0–10.2; ~5,765,237 people), annual prevalence of GP reported-and-diagnosed asthma was 8.2% (95% CI 8.2–8.2; ~5,215,607 people) and annual prevalence of GP reported-and-diagnosed-and-treated asthma was 6.0% (95% CI 6.0–6.0; ~3,946,796 people). In 2011–12, asthma resulted in an estimated: 6,392,670 primary-care consultations; 93,916 inpatient-care episodes; 1,864 (317 paediatric and 1,547 adult) intensive-care unit episodes; 36,800 disability living allowance (DLA) claims; and 1,160 deaths. The estimated cost of asthma in the UK was at least £1.1billion in 2011–12: 75% of this was for primary-care (60% prescribing and 15% consultations), 13% for DLA claims, and 10% for hospital care. <h3>Conclusions</h3> We found that asthma is very common, affecting at least 3.95 million people, and that it is responsible for substantial morbidity, healthcare and societal costs in the UK. Setting ambitious targets for improving asthma outcomes is paramount and resources should be targeted to improving community-based prescribing decisions and reducing the risk of asthma exacerbations and associated hospitalisations and deaths. <h3>Funding</h3> Asthma UK, with additional support from the Edinburgh Health Services Research Unit and Farr Institute, UK.
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
Authors: Xiaoli Ma, Gwénaël Le Teuff, Benjamin Lacas, Ming Sound Tsao, Stephen Graziano, Jean-Pierre Pignon, Jean-Yves Douillard, Thierry Le Chevalier, Lesley Seymour, Martin Filipits, Robert Pirker, Pasi A. Jänne, Frances A. Shepherd, Elisabeth Brambilla, Jean-Charles Soria, Pierre Hainaut
Journal: Journal of Thoracic Oncology (2016)